The company completed strategic acquisitions in 2025, acquiring Biosensis Pty Ltd in Life Sciences and Interlog USA, Inc. in Logistics to broaden market reach and capabilities.

Key 2025 financials show revenues of $207.443 million (up 13.2% year over year), gross profit of $64.993 million (up 15.6%), operating income of $6.434 million, net income of $5.657 million, and diluted earnings per share of $4.69, reflecting year-over-year improvement from 2024.

Strategic focus combines organic growth with acquisitions, supported by capital actions such as reducing Santander Facility borrowings to zero by the end of September 2025 and increasing cash to about $12.04 million, while leveraging credit facilities for Life Sciences and Manufacturing.

Risks and challenges include integration of acquisitions, market and competitive pressures, manufacturing and logistics operational risks, regulatory compliance for Logistics, and environmental/sustainability considerations that could affect costs and operations.

The company operates in three segments—Logistics, Life Sciences, and Manufacturing—with Logistics handling 148,000 shipments in 2025 across 28 U.S. locations plus a global network; Life Sciences produces antibodies and reagents from Davis, California and other sites; Manufacturing, via Indco, Inc., manufactures mixing equipment from New Albany, Indiana.

Management acknowledges the inherent risks of an acquisition-driven growth strategy, including potential impacts on financial condition, while staying focused on growth, capital allocation, and talent retention.

Janel Corporation’s 2025 10-K highlights growth in revenues, gross profit, operating income, net income, and earnings per share, driven by Life Sciences and Logistics performance underpinned by acquisitions.

Looking ahead, the company aims to expand the Logistics segment with new branches, revenue streams, and acquisitions, while introducing new product lines and broader distribution in Life Sciences and Manufacturing.